What Sponsors Get Wrong When Initiating an Oncology Study
By Luke Gill, Claudio Hegenberger
May 4, 2026
How CRO selection significantly influences study outcomes
6 min read
False
Advertisement
Biopharma
This Week’s Biopharma News: Wave of Antibody Approvals
April 28, 2026
FDA expands Tzield, EU clears Dupixent, and Health Canada approves denosumab antibody biosimilars
4 min read
A Regulatory Roadmap for Early-Stage Biotech
By Tim Stonehouse
April 28, 2026
From first conversations with regulators to global market strategy, early decisions shape speed, risk, and long-term success
3 min read
This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet
April 27, 2026
Lilly moves to acquire Kelonia, plus gene therapy for deafness approved
3 min read
A Reliable Cold Chain is a Health Equity Issue
By Kuntal Baveja
April 21, 2026
Why temperature-controlled logistics is a critical but overlooked foundation of equitable access to medicines
4 min read
This Week’s Biopharma News: KRAS Breakthrough and ADC Momentum
April 21, 2026
Revolution’s KRAS breakthrough, strong ADC signals from GSK, and shifting regulatory and dealmaking dynamics define this week in biopharma
3 min read
Merck Expands Protein A Capabilities with JSR Chromatography Acquisition
April 16, 2026
The company says the acquisition will strengthen downstream antibody manufacturing and help biopharma customers scale more efficiently.
Jonathan Van-Tam on COVID’s Next Phase
By James Strachan, Julian Upton
April 14, 2026
Former UK Deputy Chief Medical Officer discusses new protein-based vaccines, declining uptake, and the ongoing risks of COVID-19
4 min read
Trends and Challenges in Nitrosamine Testing: Part Two – Analytical Challenges
April 10, 2026
Sample preparation, limits of detection, and structural determination – our experts return for part two to discuss the main analytical challenges associated with nitrosamines
11 min read
GLP-1 Analysis: Riding the Wave of Peptide Innovation
By Amanda M. Guiraldelli, Piotr Alvarez, Koen Sandra
April 9, 2026
The remarkable commercial success of GLP-1 receptor agonists is fueling investment, accelerating science, and creating new analytical challenges...
12 min read
